Search

KR-20260066984-A - PROTEIN COMPOSITION, AND FOOD ITEM AND HEALTH SUPPLEMENT COMPRISING THE SAME

KR20260066984AKR 20260066984 AKR20260066984 AKR 20260066984AKR-20260066984-A

Abstract

The present invention relates to a protein composition, a food and a health supplement containing the same, wherein a protein composition according to one embodiment may include whey protein, micellar casein, and milk protein.

Inventors

  • 강주희
  • 김철홍
  • 오재근

Assignees

  • 주식회사 빙그레

Dates

Publication Date
20260512
Application Date
20241105

Claims (10)

  1. Protein composition comprising whey protein, micellar casein, and milk protein.
  2. In Article 1, The above whey protein is a protein composition included in an amount of 50 to 85 weight% based on the total weight of the protein composition.
  3. In Article 1, The above micellar casein is included in a protein composition at 4 to 20 weight percent based on the total weight of the protein composition.
  4. In Article 1, The above milk protein is a protein composition included in an amount of 5 to 20 weight% based on the total weight of the protein composition.
  5. In Article 1, A protein composition comprising, based on the total weight of the protein composition, 70 to 85 weight% of the whey protein, 5 to 15 weight% of the micellar casein, and 5 to 15 weight% of the milk protein.
  6. In Article 1, Protein composition further comprising isolated soy protein.
  7. In Paragraph 6, The above isolated soy protein is a protein composition included in an amount of 20 to 30 weight% based on the total weight of the protein composition.
  8. In Paragraph 6, A protein composition comprising, based on the total weight of the protein composition, 50 to 65 weight% of the whey protein, 5 to 10 weight% of the micellar casein, 5 to 15 weight% of the milk protein, and 20 to 30 weight% of the isolated soy protein.
  9. A food comprising a protein composition according to any one of claims 1 to 8.
  10. A health supplement for improving muscle strength or exercise performance comprising a protein composition according to any one of claims 1 to 8.

Description

Protein composition, food item and health supplement comprising the same The present invention relates to a protein composition, a food containing the same, and a health supplement. Cancer cachexia is a multi-organ metabolic disorder caused by cancer, characterized by anorexia and weight loss as major symptoms, accompanied by a decrease in muscle mass. Generally, these symptoms in cancer patients are a serious problem that adversely affects chemotherapy treatment and patient survival rates. Cancer cachexia is known to occur in approximately 80% of patients with gastrointestinal cancers, such as pancreatic, lung, and colon cancers, but is relatively rare in patients with lymphoma or breast cancer. In addition, a decrease in muscle mass is recognized as one of the physiological changes occurring in the elderly. According to the results of the National Health and Nutrition Examination Survey (IV) of Korea, muscle mass begins to decline around the age of 40 for men and after the age of 55 for women. Even among the general population, a new concept called sarcopenic obesity is emerging, in which, as people age, changes in body composition occur even if body weight does not change, leading to an increase in body fat and a decrease in muscle mass. Sarcopenia is also reported to be associated with increased falls, trauma, functional impairment, hospitalization rates, reduced quality of life, and increased mortality among patients by reducing the ability to cope with external stress due to decreased muscle strength. Sarcopenia is also associated with various diseases, and among patients with diabetes, a chronic disease, the incidence of sarcopenia in diabetic patients has been reported to be about three times higher than in the general population when considering the age, gender, body mass index, and lifestyle of the subjects. The need for modern people to prevent and improve the loss of muscle function, including such muscle mass reduction, is increasing day by day. Figure 1 is a diagram showing the results of the analysis of myostatin mRNA content in four types of muscle tissues (gastrocnemius (GC), tibialis anterior (TA), extensor digitorum longus (EDL), and soleus (SOL)) for each animal experimental group. Figure 2 is a diagram showing the results of the analysis of MuRF1 mRNA content for each animal experimental group. Figure 3 is a diagram showing the results of the analysis of FoxO3a mRNA content for each animal experimental group. Figure 4 is a diagram showing the results of the analysis of SIRT1, PGC-1α, and ATP synthase mRNA content for each animal experimental group. Figure 5 is a diagram showing the results of the GLUT4 mRNA content analysis for each animal experimental group. Figure 6 is a diagram showing the results of the analysis of BCL-2, BAX, and Apoptosis inducing factor mRNA content for each animal experimental group. Figure 7 is a diagram showing the results of the analysis of IGF1 mRNA content for each animal experimental group. Figure 8 is a diagram showing the results of the analysis of COX4I1 mRNA content for each animal experimental group. Figure 9 is a diagram showing the results of the analysis of CPT mRNA content for each animal experimental group. Figure 10 is a diagram showing the results of the analysis of SIc16a1 mRNA content for each animal experimental group. Figure 11 is a diagram showing the results of the analysis of Pyruvate kinase and Phospho fructokinase mRNA content for each animal experimental group. Figure 12 is a diagram showing the results of weekly grip strength evaluations for each animal experimental group. Figure 13 is a diagram showing the weekly hanging test evaluation results for each animal experimental group. Figure 14 is a diagram showing the results of the treadmill test evaluation before and after diet for each animal experimental group. Since the embodiments described in this specification may be modified in various different forms, the technology according to one embodiment is not limited to the embodiments described below. Furthermore, throughout the specification, the terms "comprising," "having," "containing," or "having" any component do not exclude other components but may include additional components unless specifically stated otherwise, and do not exclude elements, materials, or processes not additionally listed. In this specification, "identical or uniform" may mean that they are identical or uniform to one another within an acceptable margin of error, unless otherwise specified. For example, the statement that certain components or physical property measurements are identical may include not only that the two objects being compared are completely identical, but also that they are identical within a margin of error. Meanwhile, the statement that certain physical property measurements are identical may mean that the difference between the measurements between the objects is approximately less than 5%, specifically less than 3%, and more specifically